

In the Claims:

The following listing of claims replaces all prior versions and listings of claims in the case.

1 – 30 (Cancelled).

31. (Currently amended): A kit comprising:

- (a) ~~[[a]] an antibody~~ microarray comprising a plurality of ~~antibodies located at~~ discrete locations on a solid surface, ~~wherein the plurality of discrete locations are arranged in a spatially addressable ordered matrix, wherein the antibodies are arranged in a spatially addressable ordered matrix, wherein each discrete location comprises two or more discrete foci of an antibody;~~ and
- (b) a first reagent, for labeling a cell lysate with a first fluorescent dye, and a second reagent for labeling a cell lysate with a second fluorescent dye.

32. (Previously presented): A kit according to claim 31 further comprising instructions for comparing protein expression in two or more populations of cells or characterizing a cell based on the pattern of protein expression produced thereby.

33. (Original): A kit according to claim 31 wherein the antibodies are monoclonal antibodies, polyclonal antibodies or antibody fragments.

34. (Original): A kit according to claim 33 wherein the antibody fragments are single chain antibodies.

35. (Original): A kit according to claim 31 wherein the antibodies are recombinant antibodies.

36. (Original): A kit according to claim 31 further comprising reagents for detecting an antigen and instructions for use thereof.

37 – 50 (Cancelled).

51. (Previously presented): The kit according to claim 31 wherein the source of the antibodies at each discrete location is known.
- 52 – 53 (Cancelled).
54. (Currently amended): The kit according to claim 31 wherein the space between the discrete ~~locations-foci~~ is treated to minimize non-specific binding to the solid surface.
- 55 – 59 (Canceled).
60. (Currently amended): The kit according to claim 31, wherein between ~~0.01 nanoliters~~ 1 ng and 100 ~~nanoliters~~ ng of the antibodies are spotted at each discrete location on the solid surface.
61. (Previously presented): The kit according to claim 31, wherein the microarray comprises 600 discrete locations per square centimeter.
62. (Previously presented): The kit according to claim 51, wherein the source of the antibodies is a known hybridoma cell line.
- 63 – 65 (Canceled).
66. (Previously presented): The kit according to claim 31, wherein the plurality of antibodies recognize mammalian proteins.
- 67 – 68 (Canceled).
69. (Currently amended): The kit according to claim 31, further comprising a second antibody microarray ~~comprising a plurality of antibodies located at discrete locations on a second solid surface.~~
70. (Currently amended): A microarray comprising a plurality of discrete antibodies located at discrete locations on a solid surface, wherein the plurality of discrete locations are arranged in a spatially

addressable ordered matrix, wherein each discrete location comprises two or more discrete foci of an antibody-the antibodies are a collection of 1000 different antibodies and recognize proteins of a first species.

71. (Currently amended): The microarray according to claim 70, wherein the ~~plurality of microarray~~ comprises up to about 1000 different antibodies ~~recognize mammalian proteins.~~
72. (Currently amended): The microarray according to claim 70, wherein between 0.01 nanoliters and 400 nanoliters ~~about 1 ng to about 1 µg of the antibodies~~ each antibody is ~~are~~ spotted at each of the discrete location foci on the solid surface.
73. (Currently amended): The microarray according to claim 70, wherein the microarray comprises 600 ~~discrete-addressable~~ locations per square centimeter.
74. (Currently amended): The kit according to claim 31, wherein the microarray comprises antibodies spotted at [[at]] least 48 ~~discrete-addressable~~ locations.
75. (Currently amended): The kit according to claim 74, wherein the microarray comprises antibodies spotted at [[at]] least 90 ~~discrete-addressable~~ locations.
76. (Previously presented): The kit according to claim 31, wherein the microarray comprises a collection of 1000 different antibodies.
- 77 – 79 (Cancelled).
80. (Previously presented): The microarray according to claim 70, wherein the microarray further comprises an antigen from a cell lysate, wherein the antigen is bound to a characterized antibody located on the solid surface.
81. (Currently amended): The kit according to claim 75, wherein the microarray comprises antibodies spotted at [[at]] least 384 ~~discrete-addressable~~ locations.

82. (Currently amended): The kit according to claim 31, wherein the microarray comprises antibodies spotted at [[at]] least 60 ~~discrete~~ addressable locations, wherein the antibodies bind mammalian proteins.
83. (Currently amended): The kit according to claim 31, wherein the microarray comprises antibodies spotted at [[at]] least 192 discrete locations, wherein the antibodies bind mammalian proteins.
84. (New): The microarray according to claim 70, wherein the solid surface comprises at least one of an aldehyde-treated slide, a nitrocellulose-treated slide or a nylon-treated slide.
85. (New): The microarray according to claim 70, wherein each addressable location comprises four or more discrete foci of an antibody.
86. (New): The kit according to claim 31, wherein the amount of antibody in each of the discrete foci in each discrete location is substantially different.
87. (New): The kit according to claim 31, wherein the amount of antibody in each of the discrete foci in each discrete location is substantially the same.
88. (New): The kit according to claim 31, wherein between about 1 ng to about 1 µg of each antibody is spotted at each of the discrete foci.